An lnjectable Proresolving Delivery System for Periodontal Reconstruction
Periodontitis is a worldwide prevalent chronic inflammatory disease that affects the integrity of the periodontium and may ultimately lead to tooth loss. Resolvin E1 (RvE1) is derived from eicosapentaenoic acid (EPA), and has been shown to have a modulatory role in inflammation associated models of arthritis, colitis and periodontitis.
RvE1 has the unique ability to regulate neutrophilic infiltration, downregulates cytokines and prostaglandins, stimulates macrophage-mediated phagocytosis of cellular debris and microbes. RvE1 inhibit RANKL-induced osteoclast growth and differentiation and acts directly on osteoblasts to decrease the RANKL levels and increase the OPG levels under inflammatory conditions. In periodontitis models, RvE1 has demonstrated from topical treatment prevents and resolves ligature-induced periodontitis with regeneration of soft and hard periodontal tissues.
The professional topical application of a biologically active molecule with higher frequency is arduous, since patient compliance is necessary for success of the treatment. Thus, the overall goal of this proposal is to establish a novel local delivery system containing RvE1.
$50,000 grant from the IADR/GSK Innovation Oral Care Award